PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Drug Combinations”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1977

[Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].

Forty patients have been treated with Sinemet (L-carbidopa/L-dopa) for a period of up to two years. The results are in agreement with those in the literature. In two-thirds of cases a good to very good improvement was obtained. The principal side effects were dyskinesia, hypotonia, and gastrointestinal and psychotic symptoms, though they seldom necessitated treatment interruption. L-carbidopa/L-dopa affords a real alternative therapy in the modern treatment of Parkinson's disease with L-dopa and a decarboxylase inhibitor. Generally the dosage range was up to a maximum of one tablet three times daily. Sinemet tablets are simple and convenient to handle for both doctor and patient. Dosage titration to therapeutic efficacy can be achieved in one week to ten days without complications, though we recommended a slower titration based on individual patient reaction and requirements.

Carbidopa↗
PubMedDate not supplied

Using the electronic medical record to enhance the use of combination drugs.

The objective of this study was to increase combination drug prescriptions through the use of electronic point-of-care reminders, thereby maintaining quality while decreasing medication costs. The electronic medical record (EMR) was used to identify all patients who were potential candidates for one of the following 3 currently available combination drugs: fluticasone-salmeterol, amlodipine-benazepril, or glyburide-metformin. Point-of-care electronic reminders were attached to the medication record of the EMR for each patient, and providers were asked to consider using the available combination medication. Of the patients who had electronic reminders attached to their charts and were seen at the clinic during the study period, 47 of 175 were switched to a combination medication. A cost-savings analysis showed a total annual savings of dollars 6,159.30. Point-of-care reminders are a simple and effective tool for quality-improvement interventions. Combination drugs may play an important role in controlling medication costs.

Drug Combinations↗
PubMed2002

Combination drug therapy for gastroesophageal reflux disease.

OBJECTIVE: To evaluate the role of combination therapy with proton-pump inhibitors (PPIs) and histamine(2) receptor antagonists in gastroesophageal reflux disease (GERD). DATA SOURCES: Clinical literature identified through MEDLINE (January 1966-August 2001). Key search terms included gastroesophageal reflux, benzimidazoles; omeprazole; lansoprazole; pantoprazole; rabeprazole; receptor antagonists, histamine(2); therapy, combination drug; therapy, combined modality; and combinations, drug. DATA SYNTHESIS: Approximately 80-90% of patients show healing of reflux esophagitis after 8 weeks of once-daily PPI therapy. Patients taking PPI therapy twice daily still have nocturnal acid breakthrough (periods of gastric pH <4 lasting for > or =60 min during the night) as much as 70% of the time. The clinical application of this finding has not been shown. One trial has shown that omeprazole in the morning plus ranitidine at bedtime is not as effective as omeprazole twice daily given before the morning and evening meals at controlling nocturnal acid breakthrough. Further, 1 small trial in healthy subjects without GERD showed that the addition of a 1-time dose of ranitidine at bedtime to a twice-daily regimen of omeprazole may decrease the occurrence of nocturnal acid breakthrough. However, the clinical significance of this finding is not clear. CONCLUSIONS: No studies in patients with GERD demonstrate that the addition of histamine(2) receptor antagonists to twice-daily PPI therapy provides any further benefit above that derived from PPIs alone. The parameter used to measure the efficacy of combination regimens for GERD thus far--nocturnal acid breakthrough--has not been proven to correlate with improvement of GERD symptoms in any controlled or prospective clinical trials. Further investigation is needed to determine optimal therapy in patients refractory to standard doses of PPIs.

Anti-Ulcer Agents↗